Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 02 - 22 tags : Trial save search
Follow Live Today: CNH Industrial Capital Markets Day
Published: 2022-02-22 (Crawled : 00:00) - globenewswire.com
CNHI | $11.4 -1.55% -1.32% 15M
|
Producer Manufacturing
|
| O: -3.95%
H: 2.88%
C: -1.13%
day trial oda
CNH Industrial Ventures established to accelerate new technology adoption and nurture disruptive innovation
Published: 2022-02-22 (Crawled : 00:00) - globenewswire.com
CNHI | $11.4 -1.55% -1.32% 15M
|
Producer Manufacturing
|
| O: -3.95%
H: 2.88%
C: -1.13%
technology trial cel new technology
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
Published: 2022-02-22 (Crawled : 00:00) - biospace.com/
MRNS | $1.44 0.0% 1.5M
|
Health Technology
|
| O: -1.16%
H: 2.26%
C: 0.99%
epilepticus als trials trial one clinical trials phase 3
Gates Industrial to Host Investor Day
Published: 2022-02-22 (Crawled : 22:00) - prnewswire.com
GTES | $17.77 0.68% 0.0% 1.4M
|
Producer Manufacturing
|
| O: 0.85%
H: 1.27%
C: 0.72%
day trial
CNH Industrial presents updated 2024 Strategic Business Plan
Published: 2022-02-22 (Crawled : 22:00) - globenewswire.com
CNHI | $11.4 -1.55% -1.32% 15M
|
Producer Manufacturing
|
| O: -2.21%
H: 1.58%
C: -2.19%
trial
BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases
Published: 2022-02-22 (Crawled : 20:00) - biospace.com/
BCRX | News | $4.22 -3.65% -3.79% 4.4M
|
Health Technology
|
| O: -3.52%
H: 1.88%
C: -1.83%
bcx9930 renal trial bcx993 disease media roof enroll
Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis
Published: 2022-02-22 (Crawled : 19:00) - biospace.com/
ARMP | $2.5 -1.19% 0.0% 4.9K
|
Health Technology
|
| O: -0.2%
H: 6.55%
C: 1.6%
pa02 new drug phase 2 als clearance fibrosis application drug trial cystic fibrosis
Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control ArmⓇ Solution to Accelerate Brain Cancer Clinical Trial
Published: 2022-02-22 (Crawled : 19:00) - biospace.com/
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: -4.9%
H: 13.4%
C: 4.12%
control brain cancer trial therapeutics cel cancer train
Stanley Black & Decker To Present At The Barclays 39th Annual Industrial Select Conference
Published: 2022-02-22 (Crawled : 17:00) - prnewswire.com
SWK | $90.27 -0.52% 0.0% 1.3M
|
Consumer Durables
|
| O: -0.18%
H: 0.06%
C: -1.76%
trial conference
BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar Disorders
Published: 2022-02-22 (Crawled : 17:00) - globenewswire.com
BTAI | News | $2.7 -9.09% -10.0% 880K
|
Health Technology
|
| O: -1.78%
H: 1.69%
C: -4.06%
bxcl501 america order trial therapeutics cel phase 3
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
Published: 2022-02-22 (Crawled : 13:30) - biospace.com/
MRNA | News S | $108.82 0.86% 0.85% 3.4M
|
Health Technology
|
| O: -2.39%
H: 6.28%
C: 1.9%
respiratory trial vaccine phase 3
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
Published: 2022-02-22 (Crawled : 13:30) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: 1.5%
H: 3.77%
C: -0.49%
oto-313 phase 2 trial enroll
Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT
Published: 2022-02-22 (Crawled : 13:00) - prnewswire.com
BHVN | News 0 d | $38.72 -2.25% -0.28% 970K
|
Health Technology
|
| O: -1.15%
H: 1.44%
C: -2.83%
nurtec phase 2 phase 2/3 trial enroll
RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial
Published: 2022-02-22 (Crawled : 12:30) - renovorx.com
RNXT | $1.26 5.0% 4.76% 3.5K
|
|
| O: 1.95%
H: 3.26%
C: -3.28%
ongoing trial cancer phase 3 pancreatic enroll
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.